Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre,... by Yang, Yunpeng, Prof, Qu, Song, Prof, Li, Jingao, Prof, Hu, Chaosu, Prof, Xu, Mingjun, Prof, Li, Weidong, Prof, Zhou, Ting, MD, Shen, Liangfang, Prof, Wu, Hui, Prof, Lang, Jinyi, Prof, Hu, Guangyuan, Prof, Luo, Zhanxiong, Prof, Fu, Zhichao, Prof, Qu, Shenhong, Prof, Feng, Weineng, Prof, Chen, Xiaozhong, Prof, Lin, Shaojun, Prof, Zhang, Weimin, Prof, Li, Xiaojiang, Prof, Sun, Yan, Prof, Lin, Zhixiong, Prof, Lin, Qin, Prof, Lei, Feng, Prof, Long, Jianting, Prof, Hong, Jinsheng, Prof, Huang, Xiaoming, Prof, Zeng, Lingzhi, Prof, Wang, Peiguo, Prof, He, Xiaohui, Prof, Zhang, Ben, MS, Yang, Qing, MD, Zhang, Xiaojing, MD, Zou, Jianjun, MD, Fang, Wenfeng, Prof, Zhang, Li, Prof

Get full text

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, p... by Ma, Yuxiang, MD, Huang, Yan, MD, Zhao, Yuanyuan, MD, Zhao, Shen, MD, Xue, Jinhui, MD, Yang, Yunpeng, MD, Fang, Wenfeng, MD, Guo, Ye, Prof, Han, Yaqian, MD, Yang, Kunyu, MD, Li, Yongsheng, MD, Yang, Jun, MD, Fu, Zhenming, MD, Chen, Gang, MD, Chen, Likun, MD, Zhou, Ningning, MD, Zhou, Ting, MD, Zhang, Yaxiong, MD, Zhou, Huaqiang, Prof, Liu, Qianwen, MD, Zhu, Yi, PhD, Zhu, Hai, PhD, Xiao, Sa, PhD, Zhang, Li, Prof, Zhao, Hongyun, Prof

Get full text